Clinical Trial Results Provide the Rationale to Protect Dual HIV-specific T Cells with a Signaling-Defective HIV Fusion Inhibitor.

已完结 10 由 eijow;afjaodj 发布于 2026/1/24 10:51:14

DOI:10.1016/j.ymthe.2026.01.006
作者：Pablo Tebas,Julie K Jadlowsky,Yuqi Zhou,M Betina Pampena,George J Leslie,Nan Liu,Sriram Srivatsa,Colby R Maldini,Jingxin Wang,Chungdhak Jaming Tsang,Ola Mohamed,Josephine Romano,Beth Haggarty,Gabriela
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Coupling the HIV fusion inhibitor C34 with CXCR4 (C34-CXCR4) protected CD4 T cells from all strains of HIV. Escape from C34-CXCR4 expression proved difficult, requiring more than 21 serial p

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:WileyAluminum-Rich Molecular Sieve Interface Regulating Electron-Enriched Mn-O-Ce Active Sites for Environmental Catalysis